Acerus Pharmaceuticals (ASPCQ)
OTHER OTC:ASPCQ

Acerus Pharmaceuticals (ASPCQ) Income Statement

0 Followers

Acerus Pharmaceuticals Income Statement

Last quarter (Q ), Acerus Pharmaceuticals's total revenue was $770.00K, an increase of 31.18% from the same quarter last year. In Q, Acerus Pharmaceuticals's net income was $-4.17M. See Acerus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 3.04M$ -4.13M$ 1.08M$ 3.77M$ 7.38M$ 6.54M
Cost of Revenue
$ 1.33M$ 1.12M$ 2.01M$ 2.20M$ 10.32M$ 3.26M
Gross Profit
$ 1.71M$ -5.25M$ -929.00K$ 1.57M$ -2.95M$ 3.27M
Operating Expense
$ 27.12M$ 27.72M$ 20.33M$ 13.07M$ 10.95M$ 10.13M
Operating Income
$ -25.41M$ -32.98M$ -21.26M$ -11.50M$ -13.90M$ -6.86M
Net Non Operating Interest Income Expense
$ -5.04M$ 2.50M$ -1.87M$ -2.44M$ -1.76M$ -359.00K
Other Income Expense
$ -3.70M$ 1.66M$ -1.30M$ -2.19M$ -3.10M$ -1.36M
Pretax Income
$ -28.08M$ -33.82M$ -24.42M$ -16.13M$ -18.76M$ -8.58M
Tax Provision
--$ 0.00$ 0.00$ 29.00K$ 47.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -28.08M$ -33.82M$ -24.42M$ -16.13M$ -18.79M$ -8.62M
Basic EPS
$ -2.47$ -4.00$ -6.00---
Diluted EPS
$ -2.47$ -4.00$ -6.00---
Basic Average Shares
$ 30.78M$ 7.69M$ 4.88M---
Diluted Average Shares
$ 30.78M$ 7.69M$ 4.88M---
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 21.99M$ -28.84M$ 22.34M$ 15.27M$ 21.28M$ 13.40M
Net Income From Continuing And Discontinued Operation
$ -28.08M$ -33.82M$ -24.42M$ -16.13M$ -18.79M$ -8.62M
Normalized Income
$ -27.41M$ -33.82M$ -23.13M$ -13.94M$ -16.51M$ -7.63M
Interest Expense
$ 2.66M-$ 1.55M$ 1.61M$ 1.06M$ 370.00K
EBIT
$ -23.90M$ -36.31M$ -22.87M$ -14.51M$ -17.69M$ -8.21M
EBITDA
$ -21.05M-$ -21.86M$ -13.39M$ -15.74M$ -6.16M
Currency in USD

Acerus Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis